Marissa Chaet Brykman, JD, Virginia Streusand Goldman, PhD, Nandakumara Sarma, PhD, RPh, Hellen A. Oketch-Rabah, PhD, MSc, Deborah Biswas, JD, and Gabriel I. Giancaspro, PhD
Increase in dietary supplement use in the United States suggests a great need for clinicians to be aware of the range of their quality parameters.
AMA J Ethics. 2022;24(5):E382-389. doi:
10.1001/amajethics.2022.382.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
Lisa M. Meeks, PhD and Christopher Moreland, MD, MPH
Obstacles for applicants with disabilities illuminate admission practices that could help craft a clinical workforce that is appropriately diverse and prepared to give just, patient-centered care.
AMA J Ethics. 2021;23(12):E987-994. doi:
10.1001/amajethics.2021.987.
Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.
AMA J Ethics. 2021;23(7):E569-575. doi:
10.1001/amajethics.2021.569.